Jared Moskowitz
Price Movement Since Trade
How each stock has moved from the trade date to the most recent close.
Suspicious Timing Detected
4 flagsJared Moskowitz bought $1,001 - $15,000 in $CI on 2025-05-15, 36 days before the RAMP Act (HR4056) was introduced, a bill aiming to reduce legal exposure for non-group health insurers.
Jared Moskowitz bought $1,001 - $15,000 in $CI on 2025-05-15, 69 days before the Veterans' ACCESS Act of 2025 (HR740) was introduced, which expands the Veterans Community Care Program.
Jared Moskowitz sold $1,001 - $15,000 in $UNH on 2025-05-15, 69 days before H.J. Res. 110 was introduced, proposing a balanced budget amendment that could lead to federal spending cuts.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $HCA | HCA Healthcare, Inc. Common Stock | $1K-$15K | $385.50 | — | — | May 15, 2025 |
| BUY | $HCA | HCA Healthcare, Inc. Common Stock | $1K-$15K | $385.50 | — | — | May 15, 2025 |
| BUY | $CI | The Cigna Group Common Stock | $1K-$15K | $308.86 | — | — | May 15, 2025 |
| BUY | $CI | The Cigna Group Common Stock | $1K-$15K | $308.86 | — | — | May 15, 2025 |
| SELL | $UNH | UnitedHealth Group Incorporated Common Stock | $1K-$15K | $274.35 | — | — | May 15, 2025 |
| SELL | $UNH | UnitedHealth Group Incorporated Common Stock | $1K-$15K | $274.35 | — | — | May 15, 2025 |
| SELL | $UNH | UnitedHealth Group Incorporated Common Stock | $1K-$15K | $274.35 | — | — | May 15, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Protecting Health Care and Lowering Costs Act
Sen. Schumer introduced S. 2556 (Protecting Health Care and Lowering Costs Act) on July 30, 2025. The bill makes permanent the ACA premium tax credit expansion (eliminates the 400% FPL cap, lowers applicable percentages). In early committee stage with 46 Democratic cosponsors, passage odds are low in the divided 119th Congress, but the policy signal is structurally bullish for major ACA market insurers. Real market data shows UNH up 36.28%, HUM up 39.06%, CVS up 16.35%, and CI up 9.19% in the past 30 days — strong momentum driven by the bill's reintroduction reflecting forward pricing on increased subsidized enrollment expectations.
No Surprises Act Enforcement Act
The No Surprises Act Enforcement Act (HR4710) is an early-stage House bill that would increase balance billing penalties from $100/day to $10,000 per violation for health insurers. The bill has been referred to three committees and has a Senate companion (S2420). Despite the bearish legislative signal, major insurers including ELV (+7.71% 7-day) and HUM (+13.29% 7-day) have shown strong recent price momentum driven by other factors.
Protecting Health Care and Lowering Costs Act of 2025
HR 4849 permanently eliminates the 400% FPL cap on ACA premium tax credits and establishes zero-premium subsidies for incomes up to 150% FPL, driving 5-7M new exchange enrollees. Real market data shows $MOH (+49.46% 30-day) and $HUM (+46.46% 30-day) leading the sector as pure-play beneficiaries of the deepest subsidy expansion. $UNH (+41.62% 30-day) and $CVS (+19.62% 30-day) also rally but face offsetting factors from PBM margin and OBBBA repeal dynamics.
State-Based Universal Health Care Act of 2025
HR4406 is in very early legislative stages—referred to five committees with 34 cosponsors. No funding is authorized. The bill is not a near-term market factor for any healthcare company.
Proposing a balanced budget amendment to the Constitution of the United States.
H.J. Res. 110 is a procedural introduction of a balanced budget constitutional amendment with zero near-term market impact. The bill was referred to the House Judiciary Committee on July 23, 2025, and has had no further action. No committee hearings, no companion Senate bill, and no mechanism to allocate or appropriate any funds exist. Retail investors should ignore this bill as a market signal.
Supporting Healthy Moms and Babies Act
The 'Supporting Healthy Moms and Babies Act' (HR3762) is an early-stage bill that would mandate comprehensive maternity/newborn care coverage without cost-sharing under ACA plans. With 28 cosponsors, a companion bill in the Senate, and referral to three committees, legislative progress is early but has nominal bipartisan support. Insurers UNH and CI face increased medical costs, while diagnostic labs LH and DGX benefit from higher utilization. No dollar amount is authorized or appropriated.
RAMP Act
The RAMP Act (HR4056) is an early-stage bill that would restrict the Medicare Secondary Payer private right of action to group health plans only, granting legal relief to auto, liability, workers' compensation, and no-fault insurers. The bill is referenced to two committees and has only one cosponsor, indicating a long legislative path. For the named insurers—UnitedHealth, Cigna, Humana—the bill is largely neutral as they primarily operate group health plans, which retain existing litigation exposure.
Veterans’ Assuring Critical Care Expansions to Support Servicemembers (ACCESS) Act of 2025
The Veterans ACCESS Act (S.275), reported favorably from committee and awaiting Senate floor action, codifies community care eligibility standards that will expand veteran patient volume to private healthcare providers. Healthcare REITs $VTR, $WELL, and $SBRA are structurally positioned to benefit from increased outpatient utilization, while hospital operators $HCA and $UHS face a policy tailwind offset by recent stock price declines of -8.2% and -5.59% respectively over the last 30 days.
Veterans’ ACCESS Act of 2025
The Veterans' ACCESS Act (HR740) mandates VA referrals to private providers for eligible veterans, structurally diverting patient volume from VA facilities to commercial managed care organizations. The bill is authorization-only with no direct appropriations, but the policy mandate alone is a clear, multi-billion-dollar revenue driver for $UNH, $HUM, $MOH, $CI, and $CVS. Real market data shows these stocks already pricing in passage: 30-day gains of +34.5% ($UNH), +39.6% ($HUM), +44.6% ($MOH), +7.3% ($CI), and +15.4% ($CVS) since late March 2026.
ADAPT Act
The ADAPT Act (S2356) is a zero-funding authorization bill that would expand Medicare/Medicaid/CHIP coverage to include supervised psychology trainees. It remains in early committee stage with minimal support. Recent rallies in UNH, HUM, and CVS (+41.6%, +35.86%, +15.55% over 30 days) are driven by unrelated factors such as the April 18 Executive Order on psychedelic therapies, not this bill. No actionable market impact.
Other Filings by Jared Moskowitz
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.